Myasthenia Gravis Market Research Report – Global Forecast till 2027

Myasthenia Gravis Market: By Type (Ocular Myasthenia Gravis, Congenital Myasthenia Gravis, Generalized Myasthenia Gravis, Transient Myasthenia Gravis and Others), (Diagnosis and Treatment), End User (Hospitals and Clinics, Diagnostic Centers and Academic and Research Organizations) and By Region-Global Forecast Till 2027

ID: MRFR/HC/5800-CR | January 2019 | Region: Global | 175 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data and TOC.

Market Snapshot


The global myasthenia gravis market is projected to witness a compound annual growth rate of 9.61% during the forecast period (2018-2023). There has been a substantial rise in prevalence of myasthenia gravis in recent years, which led to a sharp increase in treatment demand. Myasthenia gravis (MG) is an autoimmune neuromuscular disorder, its primary impact include decrease in the concentration of AChRs on the muscle endplate membrane. North America and Latin America collectively make the largest contribution to the growth of the global myasthenia gravis market. Meanwhile, Europe and Asia Pacific hold the second and third spot in terms of value.


Synopsis


This MRFR perspective presents a holistic outlook on the global myasthenia gravis market. It also includes a revenue forecast till 2023 along with a three-year (2015-2018) historical analysis. Market dynamics such as drivers, restraints and opportunities have been thoroughly discussed in the research document. Also, market assessment based on various types of myasthenia gravis (ocular myasthenia gravis, congenital myasthenia gravis, generalized myasthenia gravis, transient myasthenia gravis and others) is also available in the report.


Report Coverage


Historical market trends, market dynamics, forecast, market value by region as well as by segmentation, country-level analysis for each market segment, key player’s market share analysis and market factor analysis which covers supply chain and Porter’s five forces analysis of the market


Companies Covered


GE Healthcare, Alexion Pharmaceuticals, Inc, Novartis AG, Pfizer Inc., Boston Scientific Corporation, CSL Behring, Medtronic Plc., Baxter, Grifols S.A., Shire, Koninklijke Philips N.V., and Valeant Pharmaceuticals International, Inc.


Research Methodology


MRFR is committed to deliver a highly accurate market outlook, deep-diving into the crux. This is done by following a systematic and fail-safe research structure. It ensures market sizing and evaluation is conducted with an unbiased viewpoint and presentation of error-free perspective. A combination of primary and secondary research input allows accountability of market findings. For this, a wide variety of research material is amassed, which includes surveys, bites from c-level executives, expert opinion, white paper, SEC filing, paid database services etc. Emphasis is placed on delivering actional market insights though extensive data assessment. In addition, verification of research findings involves undertaking of top-down and bottom-up approaches.


Other Description



  • Market Denomination- USD Mn

  • Base Year- 2017

  • Forecast Period- from 2018 to 2023


For the scope of the research, MRFR’s report offers a comprehensive segmental analysis of the global market for myasthenia gravis


By Type



  • Ocular myasthenia gravis

  • Congenital myasthenia gravis

  • Generalized myasthenia gravis

  • Transient myasthenia gravis

  • Others


By Diagnosis and Treatment



  • Diagnosis

    • Lab-based test

    • Electrodiagnostic testing & imaging



  • Treatment

    • Cholinesterase inhibitors

    • Immunosuppressive drugs

    • Plasmapheresis and intravenous immunoglobulin

    • Thymectomy




End User



  • Hospitals and Clinics

  • Diagnostic Centers

  • Academic and Research organizations


By Region



  • North America

  • Europe

  • Asia Pacific

  • The Middle East & Africa (MEA)

  • Latin America



Frequently Asked Questions (FAQ) :


Myasthenia Gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body.

Myasthenia Gravis Market is expected to exhibit a strong 7.5% CAGR over the forecast period from 2020 to 2027.

Increasing prevalence of neuromuscular disorders and the growing awareness about the disease are the major drivers for the Myasthenia Gravis Market.

Americas accounted for the largest share in the market in 2016.

Leading players in the Myasthenia Gravis Market include Valeant, Piramal Healthcare, and Biogen Inc., among others.

The Global myasthenia gravis market is projected to reach a valuation of USD 3094.10 Mn by the year 2023. The market will capture 9.61% CAGR during the forecast period (2018-2023).  Rise in incidence rate is one of the major factors driving the demand for myasthenia gravis treatment.  In most of the cases, the condition occurs due to the abnormal size of the thymus gland and the development of benign tumors of the thymus. Owing to the rising cases of MG and related complications, various government bodies and private foundations, such as the Myasthenia Gravis Foundation of America (MGFA), and the Muscular Dystrophy Association (MDA) are actively working on curtailing the effect of MG.


The treatment options have increased in recent years, with better outcomes. Awareness programs and initiatives taken by non-profit organizations are contributing to the growth of the market. In addition to this, rising research funding for myasthenia gravis is likely to create market opportunities in years to come.  However, the high cost of treatment is likely to continues to hinder market proliferation to a certain extent.


Segmental Analysis


The segmental analysis of the global myasthenia gravis market is conducted on the basis of type, diagnosis and treatment, end-user, and region.


 On the basis of type, the market has been segmented into ocular myasthenia gravis, congenital myasthenia gravis, generalized myasthenia gravis, transient myasthenia gravis, and others. In 2017, the generalized myasthenia gravis segment accounted for 44.7% share of market. The segment is expected to exhibit a CAGR of 11.90% during the forecast period and reach a valuation of USD 1526.66 Mn. Generalized myasthenia gravis is the most common type of MG which is characterized by weakness in the arms, legs and neck, as well as the torso.


Based on diagnosis and treatment, the market has been segmented into diagnosis and treatment. The diagnosis segment is further sub-segmented into lab-based test, electrodiagnostic testing, and imaging. The   treatment   segment   is   further sub-segmented into cholinesterase inhibitors, immunosuppressive drugs, plasmapheresis and intravenous immunoglobulin, and thymectomy. In 2017, the treatment segment accounted for 69.6% and stood at a valuation of over 1200 Mn. During the forecast period, the segment is expected to exhibit a CAGR of 9.52%.


Based on end user, the market has been segmented into hospitals and clinics, diagnostic centers, and academic and research organizations. The hospital and clinics segment accounted for 55.8% market share in terms of value. The segment is likely to increase at double-digit CAGR over 2023.


Regional Analysis


Based on region, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas currently account the largest market share and the trend is likely to continue throughout the assessment period. The region’s dominant position in the market can be attributed to factors such as presence of a robust healthcare system, and high healthcare expenditure partly supporting the growth of the market in Americas. The region is home to a large number of medical service provider, which puts the region in a favorable positing. North America is expected to make a relatively higher contribution to the market’s growth as compared to Latin America. Strong economy and government support in R&D activities provide an impetus to the market in North America.


Europe is the second largest market for myasthenia gravis. The region will continue to present lucrative opportunities to market players. Accessibility to world-class healthcare facilities, favorable reimbursement policies and an expanding geriatric population are some of the factors propelling the market in Europe.


The market in Asia-Pacific is projected to witness the fastest CAGR during the assessment period. Expanding patient pool and increased healthcare penetration is linked with the exponential growth of the market in the region. Moreover, the governments in various APAC countries are striving to improve healthcare systems and meet global standards. High rate of prevalence of chronic and acute disorders coupled with efforts to deliver affordable care is likely to have a positive impact on the region’s market.


Competition Tracking


Some of the leading market participants include Alexion Pharmaceuticals, Inc, GE Healthcare, Pfizer Inc., Novartis AG, CSL Behring, Boston Scientific Corporation, Baxter, Grifols S.A., Medtronic Plc., Koninklijke Philips N.V., Shire, Valeant Pharmaceuticals International, Inc.

1 Report Prologue


2 Executive Summary


3 Market Introduction

3.1 Definition 20

3.2 Scope of the Study 20

3.3 Assumptions & Limitations 20

3.3.1 Assumptions 20

3.3.2 Limitations 20

3.4 Market Structure 20

4 Research Methodology

4.1 Research Process 22

4.2 Primary Research 23

4.3 Secondary Research 24

4.4 Market Size Estimation 24

4.5 Forecast Model 25

5 Market Dynamics

5.1 Introduction 27

5.2 Drivers 27

5.2.1 Rising Research Funding for Myasthenia Gravis 27

5.2.2 Awareness Programs and Initiatives Taken by Associations 28

5.2.3 Rising Prevalence of MG 28

5.3 Restraints 29

5.3.1 High Cost of Treatment Associated with Myasthenia Gravis 29

5.4 Opportunities 29

5.4.1 Strong pipeline 29

5.5 Market Trends 29

5.6 Macroeconomic Indicators 30

5.7 Clinical Trials Data 30

6 Market Factor Analysis

6.1 Porter’s Five Forces Analysis 33

6.1.1 Bargaining Power of Suppliers 33

6.1.2 Bargaining Power of Buyers 34

6.1.3 Threat of New Entrants 34

6.1.4 Threat of Substitutes 34

6.1.5 Intensity of Rivalry 34

6.2 Supply Chain Analysis 35

6.2.1 R&D 35

6.2.2 Manufacturing 35

6.2.3 Distribution 35

6.2.4 Marketing & Sales 35

6.2.5 Post-Sales Monitoring 36

6.3 Pricing Analysis 36

7 Myasthenia Gravis Disease Market, by Diagnosis & Treatment

7.1 Introduction 38

7.1.1 Diagnosis 39

7.1.2 Treatment 41

8 Myasthenia Gravis Disease Market, by End User

8.1 Introduction 43

8.1.1 Hospitals & Clinics 44

8.1.2 Diagnostic Centers 44

8.1.3 Academic & Research Organizations 45

9 Global Myasthenia Gravis Disease Market, by Region

9.1 Introduction 47

9.2 Americas 49

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.2.1 North America 52

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.2.1.1 US 54

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.2.1.2 Canada 56

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.2.2 South America 58

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.3 Europe 60

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.3.1 Western Europe 63

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.3.1.1 Germany 65

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.3.1.2 France 67

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.3.1.3 UK 69

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.3.1.4 Italy 71

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.3.1.5 Spain 73

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.3.1.6 Rest of Western Europe 75

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.3.2 Eastern Europe 77

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.4 Asia-Pacific 79

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.4.1 China 82

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.4.2 Japan 84

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.4.3 India 86

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.4.4 Australia 88

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.4.5 South Korea 90

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.4.6 Rest of Asia-Pacific 92

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.5 Middle East & Africa 94

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.5.1 Middle East 97

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

9.5.2 Africa 99

Myasthenia Gravis Disease Market, by Diagnosis & Treatment

Myasthenia Gravis Disease Market, by End User

10 Competitive Landscape

10.1 Introduction 102

11 Company Profile

11.1 Alexion Pharmaceuticals, Inc 104

11.1.1 Company Overview 104

11.1.2 Financial Overview 104

11.1.3 Products/Services Offered 105

11.1.4 Key Developments 105

11.1.5 SWOT Analysis 105

11.1.6 Key Strategy 105

11.2 GE Healthcare 106

11.2.1 Company Overview 106

11.2.2 Financial Overview 106

11.2.3 Products/Services Offered 107

11.2.4 Key Developments 107

11.2.5 SWOT Analysis 107

11.2.6 Key Strategy 107

11.3 Pfizer Inc. 108

11.3.1 Company Overview 108

11.3.2 Financial Overview 108

11.3.3 Products/Services Offering 108

11.3.4 Key Developments 109

11.3.5 SWOT Analysis 109

11.3.6 Key Strategy 109

11.4 Novartis AG 110

11.4.1 Company Overview 110

11.4.2 Financial Overview: 110

11.4.3 Products/Services Offered 111

11.4.4 Key Developments 111

11.4.5 SWOT Analysis 111

11.4.6 Key Strategy 111

11.5 F. Hoffmann-La Roche AG 112

11.5.1 Company Overview 112

11.5.2 Financial Overview 112

11.5.3 Products/Services Offered 113

11.5.4 Key Developments 113

11.5.5 SWOT Analysis 113

11.5.6 Key Strategy 113

11.6 CSL Behring 114

11.6.1 Company Overview 114

11.6.2 Financial Overview 114

11.6.3 Products/Services Offered 115

11.6.4 Key Developments 115

11.6.5 SWOT Analysis 115

11.6.6 Key Strategy 115

11.7 Boston Scientific Corporation 116

11.7.1 Company Overview 116

11.7.2 Financial Overview 116

11.7.3 Products/Services Offered 117

11.7.4 Key Developments 117

11.7.5 SWOT Analysis 117

11.7.6 Key Strategy 117

11.8 Baxter 118

11.8.1 Company Overview 118

11.8.2 Company Overview 118

11.8.3 Products/Services Offered 119

11.8.4 SWOT Analysis 119

11.8.5 Key Developments 119

11.8.6 Key strategy 119

11.9 Grifols S.A. 120

11.9.1 Company Overview 120

11.9.2 Financial Overview 120

11.9.3 Products/Services Offered 121

11.9.4 Key Developments 121

11.9.5 SWOT Analysis 121

11.9.6 Key Strategy 121

11.10 Medtronic Plc 122

11.10.1 Company Overview 122

11.10.2 Financial Overview 122

11.10.3 Products/Services Offered 122

11.10.4 Key Developments 123

11.10.5 SWOT Analysis 123

11.10.6 Key Strategy 123

11.11 Koninklijke Philips N.V. 124

11.11.1 Company Overview 124

11.11.2 Financial Overview 124

11.11.3 Products/Services Offered 124

11.11.4 Key Developments 125

11.11.5 SWOT Analysis 125

11.11.6 Key Strategy 125

11.12 Shire 126

11.12.1 Company Overview 126

11.12.2 Financial Overview 126

11.12.3 Products/Services Offered 126

11.12.4 Key Developments 127

11.12.5 SWOT Analysis 127

11.12.6 Key Strategy 127

11.13 Valeant Pharmaceuticals International, Inc. 128

11.13.1 Company Overview 128

11.13.2 Financial Overview 128

11.13.3 Products/Services Offered 129

11.13.4 Key Developments 129

11.13.5 SWOT Analysis 129

11.13.6 Key Strategy 129

11.14 Avadel Pharmaceuticals plc 130

11.14.1 Company Overview 130

11.14.2 Financial Overview 130

11.14.3 Products/Services Offered 130

11.14.4 Key Developments 130

11.14.5 SWOT Analysis 131

11.14.6 Key Strategy 131

11.15 Teva Pharmaceutical Industries Ltd 132

11.15.1 Company Overview 132

11.15.2 Financial Overview 132

11.15.3 Products/Services Offered 133

11.15.4 Key Developments 133

11.15.5 SWOT Analysis 133

11.15.6 Key Strategy 133

12 Appendix

12.1 Discussion Blue Print 135

13 List of Tables

TABLE 1 MARKET SYNOPSIS 18

TABLE 2 PRIMARY INTERVIEWS 22

TABLE 3 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 38

TABLE 4 GLOBAL MYASTHENIA GRAVIS DISEASE DIAGNOSIS MARKET, BY REGION 2015–2023 (USD MILLION) 39

TABLE 5 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 40

TABLE 6 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 40

TABLE 7 GLOBAL MYASTHENIA GRAVIS DISEASE TREATMENT MARKET, BY REGION 2015–2023 (USD MILLION) 41

TABLE 8 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 41

TABLE 9 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 43

TABLE 10 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, BY HOSPITALS & CLINICS, 2015–2023 (USD MILLION) 44

TABLE 11 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSTIC CENTERS, 2015–2023 (USD MILLION) 44

TABLE 12 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, BY ACADEMIC & RESEARCH ORGANIZATIONS, 2015–2023 (USD MILLION) 45

TABLE 13 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, BY REGION 2015–2023 (USD MILLION) 48

TABLE 14 AMERICAS MYASTHENIA GRAVIS DISEASE MARKET, BY REGION, 2015–2023 (USD MILLION) 49

TABLE 15 AMERICAS MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 49

TABLE 16 AMERICAS MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 50

TABLE 17 AMERICAS MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 50

TABLE 18 AMERICAS MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 51

TABLE 19 AMERICAS MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 51

TABLE 20 NORTH AMERICA MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 52

TABLE 21 NORTH AMERICA MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 52

TABLE 22 NORTH AMERICA MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 52

TABLE 23 NORTH AMERICA MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 53

TABLE 24 NORTH AMERICA MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 53

TABLE 25 US MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 54

TABLE 26 US MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 54

TABLE 27 US MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 54

TABLE 28 US MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 55

TABLE 29 US MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 55

TABLE 30 CANADA MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 56

TABLE 31 CANADA MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 56

TABLE 32 CANADA MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 56

TABLE 33 CANADA MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 57

TABLE 34 CANADA MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 57

TABLE 35 SOUTH AMERICA MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 58

TABLE 36 SOUTH AMERICA MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 58

TABLE 37 OUTH AMERICA MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 58

TABLE 38 SOUTH AMERICA MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 59

TABLE 39 SOUTH AMERICA MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 59

TABLE 40 EUROPE MYASTHENIA GRAVIS DISEASE MARKET, BY REGION, 2015–2023 (USD MILLION) 60

TABLE 41 EUROPE MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 61

TABLE 42 EUROPE MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 61

TABLE 43 EUROPE MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 61

TABLE 44 EUROPE MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 62

TABLE 45 EUROPE MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 62

TABLE 46 WESTERN EUROPE MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 63

TABLE 47 WESTERN EUROPE MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 63

TABLE 48 WESTERN EUROPE MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 63

TABLE 49 WESTERN EUROPE MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 64

TABLE 50 WESTERN EUROPE MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 64

TABLE 51 GERMANY MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 65

TABLE 52 GERMANY MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 65

TABLE 53 GERMANY MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 65

TABLE 54 GERMANY MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 66

TABLE 55 GERMANY MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 66

TABLE 56 FRANCE MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 67

TABLE 57 FRANCE MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 67

TABLE 58 FRANCE MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 67

TABLE 59 FRANCE MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 68

TABLE 60 FRANCE MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 68

TABLE 61 UK MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 69

TABLE 62 UK MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 69

TABLE 63 UK MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 69

TABLE 64 UK MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 70

TABLE 65 UK MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 70

TABLE 66 ITALY MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 71

TABLE 67 ITALY MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 71

TABLE 68 ITALY MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 71

TABLE 69 ITALY MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 72

TABLE 70 ITALY MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 72

TABLE 71 SPAIN MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 73

TABLE 72 SPAIN MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 73

TABLE 73 SPAIN MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 73

TABLE 74 SPAIN MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 74

TABLE 75 SPAIN MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 74

TABLE 76 REST OF WESTERN EUROPE MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 75

TABLE 77 REST OF WESTERN EUROPE MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 75

TABLE 78 REST OF WESTERN EUROPE MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 76

TABLE 79 REST OF WESTERN EUROPE MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 76

TABLE 80 REST OF WESTERN EUROPE MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 76

TABLE 81 EASTERN EUROPE MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 77

TABLE 82 EASTERN EUROPEMYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 77

TABLE 83 EASTERN EUROPEMYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 78

TABLE 84 EASTERN EUROPE MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 78

TABLE 85 EASTERN EUROPE MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 78

TABLE 86 ASIA-PACIFIC MYASTHENIA GRAVIS DISEASE MARKET, BY COUNTRY, 2015–2023 (USD MILLION) 79

TABLE 87 ASIA-PACIFIC MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 80

TABLE 88 ASIA-PACIFIC MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 80

TABLE 89 ASIA-PACIFIC MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 80

TABLE 90 ASIA-PACIFIC MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 81

TABLE 91 ASIA-PACIFIC MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 81

TABLE 92 CHINA MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 82

TABLE 93 CHINA MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 82

TABLE 94 CHINA MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 82

TABLE 95 CHINA MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 83

TABLE 96 CHINA MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 83

TABLE 97 JAPAN MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 84

TABLE 98 JAPAN MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 84

TABLE 99 JAPAN MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 84

TABLE 100 JAPAN MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 85

TABLE 101 JAPAN MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 85

TABLE 102 INDIA MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 86

TABLE 103 INDIA MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 86

TABLE 104 INDIA MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 86

TABLE 105 INDIA MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 87

TABLE 106 INDIA MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 87

TABLE 107 AUSTRALIA MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 88

TABLE 108 AUSTRALIA MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 88

TABLE 109 AUSTRALIA MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 88

TABLE 110 AUSTRALIA MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 89

TABLE 111 AUSTRALIA MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 89

TABLE 112 SOUTH KOREA MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 90

TABLE 113 SOUTH KOREA MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 90

TABLE 114 SOUTH KOREA MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 90

TABLE 115 SOUTH KOREA MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 91

TABLE 116 SOUTH KOREA MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 91

TABLE 117 REST OF ASIA-PACIFIC MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 92

TABLE 118 REST OF ASIA-PACIFIC MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 92

TABLE 119 REST OF ASIA-PACIFIC MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 92

TABLE 120 REST OF ASIA-PACIFIC MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 93

TABLE 121 REST OF ASIA-PACIFICMYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 93

TABLE 122 MIDDLE EAST & AFRICA MYASTHENIA GRAVIS DISEASE MARKET, BY REGION 2015–2023 (USD MILLION) 94

TABLE 123 MIDDLE EAST & AFRICA MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 94

TABLE 124 MIDDLE EAST & AFRICA MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 95

TABLE 125 MIDDLE EAST & AFRICA MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 95

TABLE 126 MIDDLE EAST & AFRICA MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 96

TABLE 127 MIDDLE EAST & AFRICA MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 96

TABLE 128 MIDDLE EAST MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 97

TABLE 129 MIDDLE EASTMYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 97

TABLE 130 MIDDLE EAST MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 97

TABLE 131 MIDDLE EAST MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 98

TABLE 132 MIDDLE EAST MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 98

TABLE 133 AFRICA MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 99

TABLE 134 AFRICA MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS TYPE, 2015–2023 (USD MILLION) 99

TABLE 135 AFRICA MYASTHENIA GRAVIS DISEASE MARKET, BY LAB BASED TEST TYPE, 2015–2023 (USD MILLION) 99

TABLE 136 AFRICA MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE, 2015–2023 (USD MILLION) 100

TABLE 137 AFRICA MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 100

TABLE 138 TOP MANUFACTURERS IN THE GLOBAL MYASTHENIA GRAVIS DISEASE MARKET 102


14 List of Figures

FIGURE 1 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET: MARKET STRUCTURE 20

FIGURE 2 RESEARCH PROCESS 22

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 25

FIGURE 4 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET: MARKET DYNAMICS 27

FIGURE 5 PORTER’S FIVE FORCES ANALYSIS OF GLOBAL MYASTHENIA GRAVIS DISEASE MARKET 33

FIGURE 6 SUPPLY CHAIN: MYASTHENIA GRAVIS DISEASE MARKET 35

FIGURE 7 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION) 39

FIGURE 8 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, BY END USER, 2015–2023 (USD MILLION) 43

FIGURE 9 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, BY REGION 2015–2023 (USD MILLION) 48

FIGURE 10 AMERICAS MYASTHENIA GRAVIS DISEASE MARKET SHARE, BY REGION, 2017 (%) 49

FIGURE 11 EUROPE MYASTHENIA GRAVIS DISEASE MARKET SHARE, BY COUNTRY/REGION, 2017 (%) 60

FIGURE 12 ASIA-PACIFIC MYASTHENIA GRAVIS DISEASE MARKET SHARE, BY COUNTRY/REGION, 2017 (%) 79

FIGURE 13 MIDDLE EAST & AFRICA MYASTHENIA GRAVIS DISEASE MARKET SHARE, BY COUNTRY/REGION, 2017 (%) 94



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.

Global Myasthenia Gravis Market: Company Landscape


The global myasthenia gravis market is characterized by the presence of many global, regional, and local vendors. The market is highly competitive with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront the market growth. The vendors compete based on cost, quality, and reliability. It is decisive for the vendors to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive and growing market environment.


The growth of the market vendors is dependent on market conditions, government support, and industry development. Thus, vendors should focus on expanding geographically and improving their products. They primarily focus on the development of novel products. Although the international players are dominating the market, regional and foreign players with small market shares also have a presence. The international players may strengthen their presence worldwide through acquisitions during the forecast period. It has also been forecast that improvement of the global economic scenario combined with efforts to enhance infrastructure in emerging nations, is fueling the market growth, thereby making it an ideal time for new products and to increase the global market share.


Alexion Pharmaceuticals, Inc., is major player in the global myasthenia gravis market. The company is focused on serving patients and families affected by rare diseases through the discovery, development, and commercialization of life-changing therapies. Alexion Pharmaceuticals, Inc., is best known for its development of Soliris, a drug used to treat rare disorders, atypical hemolytic uremic syndrome, and paroxysmal nocturnal hemoglobinuria. In October 2017, FDA Approved Soliris (eculizumab) for the treatment of patients with Generalized Myasthenia Gravis (gMG).


 In September 2018, Alexion Pharmaceuticals, Inc. announced positive results from the Phase 3 PREVENT study of Soliris (eculizumab) in patients with anti-aquaporin-4 (AQP4) autoantibody-positive neuromyelitis optica spectrum disorder (NMOSD). Moreover, Alexion announced that it has entered into a definitive agreement for the company to acquire Syntimmune, a clinical-stage biotechnology company developing antibody therapeutics targeting the neonatal Fc receptor.


Hoffmann-La Roche AG is a healthcare company, with genuinely differentiated solutions in oncology, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. The company is dedicated to developing innovative diagnostic tests and medicines which will help the patients and the world. The products offered by the company help in tapping the world’s two third of all the diseases which are either still not treated effectively or not treated at all. Geographically, the company operates in North America, Europe, Latin America, Africa, and Asia-Oceania.

Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical and medicinal device organization that creates, develops, and showcases an expansive scope of prescription and non-prescription pharmaceutical products that have an important effect on patients' lives all through more than 100 nations. Valeant's essential focus is in the areas of dermatology and eye health.